- NRx Pharmaceuticals Inc (NASDAQ:NRXP) shares are down Friday as it evaluated whether there are any conditions or events that could raise substantial doubt about its ability to continue as a going concern within one year beyond the date of filing its annual report.
- The company has generated no revenues, has incurred operating losses since inception, and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable.
- Related: Monitoring Board Recommends NRx Pharma’s Suicidal Bipolar Depression Study To Continue Enrollment.
- The company depends on obtaining the necessary equity and/or debt financing to continue operations and cannot make any assurances that sales of its lead product, NRX-101, will commence in the near term, or that additional financing will be available to it.
- This could negatively impact the company’s business and operations and could also reduce the company’s operations.
- As of December 31, 2022, the cash balance was $20.1 million.
- Price Action: NRXP shares are down 10.58% at $0.6691 on the last check Friday.
Bitcoin, Ethereum, Dogecoin Fall Amid Regulatory Uncertainty: Analyst Predicts Apex Crypto Set To Plummet 50% This Year, But Says No Need To Panic
Major cryptocurrencies witnessed a setback on Thursday, as they retraced their gains from the previous day. This was largely due to investors keeping a close eye on the ongoing debt ceiling talks in Washington D.C. and the latest regulatory actions.